Developing biomarkers to improve surgery for vestibular schwannoma and Neurofibromatosis Type 2
Engineering protease biomarkers to guide surgical therapy for vestibular schwannoma and Neurofibromatosis Type 2
This study is looking to help people with vestibular schwannomas and Neurofibromatosis Type 2 (NF2) by finding special markers that can tell doctors how aggressive a tumor is, so they can use new technology to make surgery safer and recovery easier.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11007173 on NIH RePORTER |
What this research studies
This research focuses on improving surgical outcomes for patients with vestibular schwannomas and Neurofibromatosis Type 2 (NF2) by identifying specific biomarkers that can help classify aggressive tumors. The approach involves using advanced nanotechnology tools to enhance the precision of tumor removal during surgery, which is currently the only treatment option available. By understanding the mechanisms behind tumor growth and cystic degeneration, the research aims to provide surgeons with better intraoperative guidance, potentially reducing complications and improving recovery for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with vestibular schwannomas or Neurofibromatosis Type 2, particularly those experiencing aggressive tumor growth or cystic degeneration.
Not a fit: Patients with sporadic vestibular schwannomas that do not exhibit aggressive characteristics may not receive significant benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective surgical techniques that minimize complications and improve quality of life for patients with vestibular schwannomas and NF2.
How similar studies have performed: While the approach of using biomarkers and nanotechnology in surgical settings is innovative, similar research has shown promise in improving surgical outcomes in other tumor types.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Ren, Yin — Ohio State University
- Study coordinator: Ren, Yin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.